Samuele Cortese, MD, PhD: Balancing Therapy with Medication for ADHD

Video

Medication might be best used as a first-line option for patients with ADHD.

Striking the balance between pharmacological treatment and non-pharmacological therapies is important for basically every psychiatric condition, including attention-deficit/hyperactivity disorder (ADHD).

Because ADHD is often diagnosed in pediatric patients, there are many challenges in treating this patient population. However, there are answers that have proven effective for the majority of patients.

In an interview with HCPLive®, Samuele Cortese, MD, PhD, Professor of Child and Adolescent Psychiatry, University of Southampton, explained how important this balance of therapies is particularly important in ADHD.

“We’ve come to know in the past decade what pharmacological and non-pharmacological do is different,” Cortese said.

Cortese said if you consider the core symptoms of ADHD there is evidence showing medication is effective as the first-line treatment, decreasing the severity of the core symptoms.

Cortese also said it is not entirely clear what the impact of therapies have on reducing the severity of core ADHD symptoms, but they do play a role in treating some of the other symptoms associated with the disorder commonly found in child and adolescent patients.

However, in the end, Cortese said both options have value and should be considered for patients in an effort to treat ADHD.

Related Videos
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
Daniel Greer, PharmD: Reduction in Rehospitalizations with Antipsychotic Injections for Schizophrenia
Understanding the Link Between Substance Use and Psychiatric Symptoms, with Randi Schuster, PhD
Andrew Miller, PhD: Inventor of KarXT Discusses Pivotal EMERGENT-2 Data
© 2024 MJH Life Sciences

All rights reserved.